We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Neurology

Distinct Early Cerebral Edema Subtypes as Predictors of Outcome in Cerebral Venous Thrombosis: Insights from the CLOT-VENUS Registry

MedXY Editorial Team•Jun 27, 2026•Neurology
cerebral edema subtypesCerebral Venous Thrombosiscytotoxic edemafunctional outcomeglobal cerebral edema

Highlight

– Early cerebral edema in cerebral venous thrombosis (CVT) can be classified into global, cytotoxic, and vasogenic subtypes using admission neuroimaging.
– Cytotoxic and global cerebral edema independently predict worse 6-month functional outcomes.
– Cytotoxic edema is associated with increased in-hospital mortality risk.
– Global cerebral edema prolongs hospital stay, indicating a more severe clinical course.

Study Background

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

DWI-Positive Lesions in Acute Intracerebral Hemorrhage: Insights into Cerebral Small Vessel Disease and PrognosisDWI-positive lesions in acute intracerebral hemorrhage patients correlate with cerebral small vessel disease markers and predict poorer 6-month outcomes, with lesion distribution varying by small vessel disease subtype.Aug 15, 2026Successful Recanalization Boosts Functional Recovery in Minor Ischemic Stroke: Insights from the TEMPO-2 TrialSecondary analysis of the TEMPO-2 trial reveals that successful recanalization significantly improves 90-day functional outcomes in minor ischemic stroke patients with proven occlusion, with tenecteplase markedly enhancing recanalization raJun 27, 2026Inflammatory Biomarkers in Cerebral Venous Thrombosis: Prognostic Insights from the CLOT-VENUS Substudy and Meta-AnalysesHigh admission levels of NLR, PLR, MLR, and SII are independently associated with poor functional outcomes and mortality in acute cerebral venous thrombosis, offering a low-cost tool for early risk stratification.Apr 24, 2026General vs Nongeneral Anesthesia in Endovascular Thrombectomy for Large Core Strokes: Insights from the SELECT2 Trial and Related Evidence
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
This review synthesizes evidence on anesthesia approaches during endovascular thrombectomy (EVT) for large core ischemic strokes, focusing on a prespecified secondary analysis of the SELECT2 trial that shows comparable 90-day outcomes betwe
Dec 7, 2025
Evaluating Alteplase Use in Minor Ischemic Stroke: Insights from a Nationwide Chinese RegistryA nationwide Chinese registry analysis reveals no overall benefit of intravenous alteplase in minor ischemic stroke but suggests select subgroups, especially those with disabling symptoms or higher NIHSS scores, may experience improved funcOct 29, 2025
Edaravone Dexborneol in Acute Ischemic Stroke: Real-World Evidence of Enhanced Functional Recovery and SafetyIn a large multicenter cohort study, edaravone dexborneol treatment in acute ischemic stroke patients was linked to improved 90-day functional outcomes without increased adverse events, supporting its clinical utility.Oct 3, 2025